We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » RedHill Biopharma Pushes Forward With Yeliva Trials for COVID-19
RedHill Biopharma Pushes Forward With Yeliva Trials for COVID-19
RedHill Biopharma has announced positive steps in two late-stage trials evaluating its Yeliva (opaganib) for severe COVID-19 patients and said it plans to file an Emergency Use Authorization (EUA) for the drug as early as the end of the year.